Lightspeed Venture Partners
JULY 23, 2023
in India and Southeast Asia since 2008, with 11 unicorns in its portfolio. Partner Dev Khare shares optimism for the Indian market due to technological advancements. Lightspeed India is a VC fund investing $1.5B
Transformify
OCTOBER 20, 2016
The initiative launched by Transformify and supported by its valuable partner, Genashtim, will help those who can not afford the skills training to access it on - line. Since 2008, Genashtim became a partner of eCornell in Asia - the eLearning arm for Cornell University of Ithaca, New York.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
YoungUpstarts
AUGUST 22, 2013
Productivity and notetaking software maker Evernote has been growing from strength to strength since it launched into public beta in 2008, and to date has grown to some 66 million users worldwide. In the News Evernote partnership Singapore Southeast Asia StarHub'
YoungUpstarts
APRIL 22, 2014
” Golden Gate Ventures , which has incubated 18 companies across 6 countries in Asia, estimates that the number of companies across Southeast Asia to receive Series A financing will double in 2014. “In 2010 I traveled Asia, meeting over 80 startups from a dozen countries.
thebarefootvc
JUNE 15, 2014
While credit was relatively easy to obtain in the developed markets for much of the last 20 years, the 2008 economic crisis made it more difficult for even the middle class and small businesses to obtain loans. Low cost medical devices: In 2009 in India, GE partnered with Wipro to launch low cost medical devices including a $500 portable ECG.
YoungUpstarts
MAY 25, 2011
Echelon , Southeast Asia’s biggest conference for technology startups, is back for its 2011 edition and looks to be even more exciting than before. Young Upstarts is a media partner of e27 and Echelon 2011. Many of these startups have all gone and made their mark – there’s Gothere.sg See you there!
Pascal's View
OCTOBER 10, 2011
The report “revealed that US venture capitalists are reducing their investment in biotechnology and medical device companies and shifting focus overseas to Europe and Asia, primarily due to regulatory obstacles at the Food and Drug Administration.” Shift focus away from the United States towards Europe and Asia.
Expert insights. Personalized for you.
60 
Let's personalize your content